Together We Thrive

Magenta Therapeutics is developing medicines to make cures possible for more patients, advancing a unique and fully integrated platform of therapies designed to reset the immune and blood system through stem cell transplant enabling more patients to live free of their diseases.

We know the patient journey involves more than just the patient – it involves family members, caregivers, health care providers, researchers and advocates, too. For questions or to request more information on resources available to patients and their families, please email us at

Clinical Trial Resources

Magenta is developing novel medicines to transform all aspects of stem cell transplant for many diseases. Clinical trials allow us to evaluate investigational new treatments to generate the safety and efficacy data needed to obtain approval of these treatments.

Current Clinical Trials:

Stanford University is currently conducting a Phase 2 trial studying MGTA-145, in combination with plerixafor, in the mobilization and engraftment of hematopoietic stem cells for autologous transplantation in multiple myeloma patients.

A Phase 2 clinical trial Phase 2 trial in collaboration with Be The Match/NMDP, is currently ongoing, to evaluate stem cell mobilization, collection, cell quality, engraftment and disease outcomes, including GvHD, which is of particular importance in the allogeneic transplant setting in AML, ALL and MDS patients.

For questions or to request more information, please email us at

Patient Organizations

Learn more about some of the organizations who are working on behalf of patients here:


For more information on the resources available to patients and their families, please email us at

Expanded Access Policy

Magenta also supports expanded access to
investigational products where there is substantial scientific evidence to
support the safety and the efficacy of a product for an indication when it is
logistically feasible and when permitted by applicable law.

Expanded access refers to the use of an
investigational therapy outside a clinical trial when the primary purpose is to
diagnose, prevent, or treat a serious condition in a patient. This is different
from a clinical trial, where more comprehensive safety and efficacy data are
collected. The intent of an expanded access program is to provide patients with
access to investigational medication for serious diseases or conditions where
there is no comparable or satisfactory alternative therapy available. We
understand the need for expanded access programs, and we recognize the
importance of having an appropriate policy.

Magenta will consider a number of factors consistent with the US Food and Drug Administration (FDA) and other regulatory agencies’ guidelines when reviewing requests for expanded access, including:

  • An independent request from a qualified and licensed treating physician submitted to that contains the requestor’s contact information as well as a description of the drug product requested, the disease to be treated, a rationale for the request, and any other relevant scientific and clinical information
  • The patient or patients to be treated have a serious or immediately life-threatening disease or condition, and there is no comparable or satisfactory alternative therapy to treat the disease or condition including approved products or enrolling in a clinical trial
  • The potential patient benefit justifies the potential risks of the treatment use, and those risks are not unreasonable in the context of the disease or condition to be treated
  • Granting expanded access would not potentially compromise the scientific validity of broader development programs or interfere with or delay current clinical trials or regulatory filings designed to make the therapy available to many more patients

The above criteria are among those that Magenta will consider in determining whether to offer expanded access for individual use.  However, Magenta cannot make any guarantee that the investigational therapy will be available for a particular patient. All individual requests will be evaluated in a fair, unbiased manner, and we anticipate acknowledging receipt of requests sent to within five (5) business days.

At this time, Magenta believes that participation in one of our clinical trials is the most appropriate way to access our investigational therapies. If you have additional questions, please speak with your physician or contact

Consistent with the 21st Century Cures Act, Magenta is publicly disclosing their policy on making investigational drugs available for expanded access and may revise this policy at any time. This website and policy will be updated with a hyperlink or other reference to the expanded access record on after such record becomes active.